Q-omics provides the consensus-scored RBM26 profile across patient tissues and cancer cell-line models. RBM26 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RBM26 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, RBM26 RNA expression shows 20,949 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LIHC, HNSC, and ACC as cancer lineages where RBM26 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBM26 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBM26 survival associations across molecular data types. RBM26 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBM26 RNA expression–survival associations across cancer types. High RBM26 expression shows unfavorable associations in LIHC, ACC, UVM and KICH, but favorable associations in SCLC and READ. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for RBM26 RNA expression.
This table summarizes RBM26 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for RBM26. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBM26 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, COAD, BLCA and STAD. The HNSC box plot shows higher RBM26 RNA expression in tumor versus normal tissue (log2 FC = +0.689, t-test p < 0.001).
This table shows molecular features associated with RBM26 in patient tissues and cancer cell lines. In patient samples, RBM26 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RBM26 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Lymphoma.
